Protagonist Therapeutics Commercialized Oral Peptide Drug
The company secured FDA approval for its second peptide-based therapy, signaling a shift toward digestible biologics.
Updated on Sept. 26, 2026 in Biotech
Live Poll
Do you believe the shift toward oral pill-form medications will make chronic disease treatment more affordable?
Protagonist Therapeutics successfully commercialized its oral psoriasis drug Icotyde earlier this year and gained FDA approval for a second peptide drug, Mimrylo, in August 2026. These developments mark a transition for the $9 billion firm in the development of orally administered peptide treatments.
Why it matters
The company's ability to deliver peptide-based drugs orally challenges the industry standard where such treatments typically require injection due to digestive degradation. This shift addresses a critical barrier in therapeutic delivery for complex systemic conditions.
Protagonist Therapeutics engineers gut-stable peptides by modeling them after closed-loop venom peptides to survive stomach digestion. The firm receives royalties of 6% to 10% on global Icotyde sales, a mechanism designed to scale with market adoption.
The players
Protagonist Therapeutics
A biopharmaceutical company specializing in the engineering of oral peptide drugs.
AbbVie
A global research-based biopharmaceutical company and manufacturer of the psoriasis treatment Skyrizi.
Novo Nordisk
A multinational pharmaceutical company focused on chronic disease treatments, including oral delivery platforms.
The details
Protagonist Therapeutics utilizes a chemical modification process to ensure peptides remain stable as they pass through the digestive tract. Traditional peptide drugs, which are chains of amino acids, are typically broken down by stomach enzymes and acids before they can reach the bloodstream. By modifying the molecular structure to mimic closed-loop venom peptides, the company produces a therapeutic capable of oral administration rather than injection.
Timeline
2025: Wall Street Journal reported J&J considered buying Protagonist.
Earlier this year: Icotyde launched commercially.
August 2026: FDA approved Mimrylo.
The Tech Race
Protagonist Therapeutics' development of oral peptides follows the broader industry trend of replacing traditional injectable delivery systems with digestible formats. This effort parallels competitive work from firms like Novo Nordisk in the race to secure oral versions of high-value biologics.
Patients may eventually see a shift away from injection-dependent psoriasis treatments in favor of oral medication options. The availability of these drugs is currently linked to the commercial rollout of Icotyde and the recent regulatory approval of Mimrylo.
The takeaway
The firm's shift from research-stage engineering to commercial-scale production highlights the viability of orally active peptide therapeutics. Investors and patients should track whether Icotyde's adoption reaches the $5 billion annual sales projection set by industry analysts.
Further reading
For more on the latest research in drug delivery methods, visit Biotech.
Source note: This article includes information reported by Tovima.
Live Poll
Do you believe the shift toward oral pill-form medications will make chronic disease treatment more affordable?
